EBV-triggered disease

Game-changing Disease Blocker Unveiled by Hornet Therapeutics

🌟 Hornet Therapeutics Ltd unveils preclinical data for HTX-201, an IDO1 blocker targeting post-transplant lymphoproliferative disease 🏥🦠